Radiation therapy for recurrent clear cell ovarian carcinoma

被引：0
|
作者：
Westhoff, Gina [1 ]
Fuh, Katherine
Longacre, Teri [2 ]
McNally, Leah [3 ]
Hsu, Joe [4 ]
Kapp, Daniel S. [5 ]
Teng, Nelson [1 ]
Chen, Lee-May [4 ]
机构：
[1] Stanford Univ, Sch Med Gynecol Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med Pathol, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med Obstet & Gynecol, Stanford, CA 94305 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Stanford Univ, Sch Med Radiat Oncol, Stanford, CA 94305 USA
来源：
GYNECOLOGIC ONCOLOGY | 2013年 / 131卷 / 01期
关键词：
D O I：
10.1016/j.ygyno.2013.07.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [21] Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
    Takano, Masashi
    Ikeda, Yuji
    Kudoh, Kazuya
    Kita, Tsunekazu
    Sasaki, Naoki
    Kikuchi, Yoshihiro
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (04) : 872 - 875
  • [22] Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Gallego, A.
    Ramon-Patino, J.
    Brenes, J.
    Mendiola, M.
    Berjon, A.
    Casado, G.
    Castelo, B.
    Espinosa, E.
    Hernandez, A.
    Hardisson, D.
    Feliu, J.
    Redondo, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (03): : 536 - 542
  • [23] Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    A. Gallego
    J. Ramon-Patino
    J. Brenes
    M. Mendiola
    A. Berjon
    G. Casado
    B. Castelo
    E. Espinosa
    A. Hernandez
    D. Hardisson
    J. Feliu
    A. Redondo
    Clinical and Translational Oncology, 2021, 23 : 536 - 542
  • [24] Evaluation of ATR Inhibitors for Targeted Therapy of Ovarian Clear Cell Carcinoma.
    Ji, Jing
    Li, Zhigui
    Sherman, Emily
    Osagie, Oloruntoba
    Mi, Shijun
    Soble, Whitney
    Li, Jessie
    Huang, Gloria
    REPRODUCTIVE SCIENCES, 2021, 28 (SUPPL 1) : 107A - 107A
  • [25] Osteopontin as a potential molecular target for ovarian clear cell carcinoma therapy.
    Matsuura, M.
    Suzuki, T.
    Tabuchi, Y.
    Habata, S.
    Tanigaki, E.
    Suzuki, M.
    Tanaka, R.
    Iwasaki, M.
    Hayakawa, O.
    Ito, E.
    Ebina, Y.
    Saito, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
    Loh, J.
    Ngoi, N. Y. L.
    Blanc-Durand, F.
    Ang, S. Y. R.
    Elias, E.
    Lai, A.
    Lim, D.
    Lim, Y. W.
    Lim, S. E.
    Low, J.
    Ng, J.
    Sundararajan, V.
    Thian, Y. L.
    Tong, P.
    Wijaya, S.
    Tan, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S532 - S533
  • [27] Evaluation of ATR Inhibitors for Targeted Therapy of Ovarian Clear Cell Carcinoma.
    Ji, Jing
    Li, Zhigui
    Sherman, Emily
    Osagie, Oloruntoba
    Mi, Shijun
    Huang, Gloria
    REPRODUCTIVE SCIENCES, 2020, 27 (SUPPL 1) : 118A - 118A
  • [28] Radiation therapy for superficial inguinal lymph node metastases from ovarian clear cell carcinoma and associated inguinal hernia
    Ishibashi, Naoya
    Maebayashi, Toshiya
    Nishimaki, Haruna
    Okada, Masahiro
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (05) : 1326 - 1330
  • [29] Targeting STAT3 as a novel therapy for ovarian clear cell carcinoma
    Bixel, Kristin L.
    Saini, Uksha
    Fowler, Jack
    Rajendran, Sneja
    Wanner, Ross
    Matsumura, Noriomi
    Hideg, Kalman
    Konishi, Ikuo
    Cohn, David
    Karrupaiyah, Selvendiran
    CANCER RESEARCH, 2015, 75
  • [30] Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
    Yamashita, Yoriko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 405 - 407
12345